Participation of the NO-cyclic GMP pathway in rofecoxib-induced antinociception

Proc West Pharmacol Soc. 2003:46:165-7.
No abstract available

MeSH terms

  • Animals
  • Anti-Inflammatory Agents, Non-Steroidal / pharmacology*
  • Arginine / pharmacology
  • Cyclic GMP / physiology*
  • Cyclooxygenase 2
  • Cyclooxygenase 2 Inhibitors
  • Cyclooxygenase Inhibitors / pharmacology*
  • Dose-Response Relationship, Drug
  • Enzyme Inhibitors / pharmacology
  • Female
  • Guanylate Cyclase / antagonists & inhibitors
  • Isoenzymes / metabolism
  • Lactones / pharmacology*
  • Molsidomine / analogs & derivatives*
  • Molsidomine / pharmacology
  • NG-Nitroarginine Methyl Ester / pharmacology
  • Nitric Oxide / physiology*
  • Nitric Oxide Donors / pharmacology
  • Nitric Oxide Synthase / antagonists & inhibitors
  • Oxadiazoles / pharmacology
  • Pain / chemically induced
  • Pain / drug therapy*
  • Prostaglandin-Endoperoxide Synthases / metabolism
  • Quinoxalines / pharmacology
  • Rats
  • Rats, Wistar
  • Sulfones
  • Uric Acid

Substances

  • 1H-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one
  • Anti-Inflammatory Agents, Non-Steroidal
  • Cyclooxygenase 2 Inhibitors
  • Cyclooxygenase Inhibitors
  • Enzyme Inhibitors
  • Isoenzymes
  • Lactones
  • Nitric Oxide Donors
  • Oxadiazoles
  • Quinoxalines
  • Sulfones
  • rofecoxib
  • Uric Acid
  • Nitric Oxide
  • linsidomine
  • Arginine
  • Molsidomine
  • Nitric Oxide Synthase
  • Cyclooxygenase 2
  • Prostaglandin-Endoperoxide Synthases
  • Guanylate Cyclase
  • Cyclic GMP
  • NG-Nitroarginine Methyl Ester